Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.20.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating Costs and Expenses:    
General and administrative $ 5,029 $ 4,580
Research and development 5,131 11,083
Total Operating Costs and Expenses 10,160 15,663
Loss from Operations (10,160) (15,663)
Other Income :    
Interest income 44 283
Total Other Income 44 283
Net Loss (10,116) (15,380)
Net Loss Attributable to Non-controlling Interest (73) (77)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (10,043) (15,303)
Preferred Stock Dividends, Income Statement Impact (254) (248)
Effect of Warrant exercise price adjustment (880) 0
Net Loss Attributable to Common Stockholders $ (12,557) $ (16,076)
Net Loss Per Share - Basic and Dilutive $ (0.66) $ (0.98)
Weighted average number of shares outstanding during the period - Basic and Dilutive 19,011,362 16,438,201
Series A Preferred Stock [Member]    
Other Income :    
Preferred Stock Dividends, Income Statement Impact $ (254) $ (248)
Series B Preferred Stock [Member]    
Other Income :    
Net Loss Attributable to Non-controlling Interest 0 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0
Preferred Stock Dividends, Income Statement Impact $ (1,380) $ (525)